Sage Therapeutics Stock News

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company wi

Sage Therapeutics, Inc. completed its rolling submission to the FDA for zuranolone in two indications. Zuranolone is a better formulation of Sage Therapeutics' marketed postpartum drug.

ATAI Life Sciences, Biogen and Sage have been highlighted in this Investment Ideas article.

Biogen (BIIB) and Sage Therapeutics (SAGE) NDA submission for zuranolone for treating MDD and PPD is based on data from two late-stage studies, LANDSCAPE and NEST.

Atai, Biogen, and Sage are working to develop new treatments for mental illness.

Atai, Biogen, and Sage are working to develop new treatments for mental illness.

Over the past 3 months, 6 analysts have published their opinion on Sage Therapeutics (NASDAQ:SAGE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company wi

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced that the companies will host a joint investor webcast to discuss the planned

CAMBRIDGE, Mass.

Sage Therapeutics, Inc. (NASDAQ:SAGE ) Q3 2022 Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants Helen Rubinstein - Director, IR Barry Greene - Chief Executive Officer Kimi Igu

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -6.94% and 3.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the st

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -6.94% and 3.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the st

Upgrades For AnaptysBio Inc (NASDAQ:ANAB), Guggenheim upgraded the previous rating of Neutral to Buy. AnaptysBio earned $1.15 in the second quarter, compared to $0.02 in the year-ago quarter. The sto

Sage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.